, , 2015.
, Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptormodified T cells for the immunotherapy of HER2-positive sarcoma, J Clin Oncol, vol.33, issue.15, pp.1688-96
Immunotherapy for osteosarcoma : genetic modification of T cells overcomes low levels of tumor antigen expression, Mol Ther, vol.17, issue.10, pp.1779-87, 2009. ,
, , 2005.
, Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production, Cancer Res, vol.65, issue.7, pp.2964-2971
Rearrangement bursts generate canonical gene fusions in bone and soft tissue tumors, Science, vol.361, issue.6405, 2018. ,
Mifamurtide for the treatment of nonmetastatic osteosarcoma, Expert Opin. Pharmacother, vol.12, pp.285-292, 2011. ,
URL : https://hal.archives-ouvertes.fr/inserm-00667530
Structure and function of ETAA16: a novel cell surface antigen in Ewing's tumours, Cancer Immunol Immunother, vol.55, issue.4, pp.363-374, 2006. ,
,
, Sarcome-13/OS2016 trial protocol: a multicentre, randomised, open-label, phase II trial of mifamurtide combined with postoperative chemotherapy for patients with newly diagnosed high-risk osteosarcoma, BMJ Open, vol.9, issue.5, p.25877
Decreased ratio of CD8+ T cells to regulatory T cells associated with decreased survival in dogs with osteosarcoma, J Vet Intern. Med, vol.24, pp.1118-1123, 2010. ,
Lysis of human chondrosarcoma cells by cytolytic T lymphocytes recognizing a MAGE-A3 antigen presented by HLA-A1 molecules, J Orthop Res, vol.25, pp.678-684, 2007. ,
Novel genes in the PAGE and GAGE family of tumor antigens found by homology walking in the dbEST database, Cancer Res, vol.59, issue.7, pp.1445-1448, 1999. ,
Biology of bone sarcomas and new therapeutic developments, Calcif Tissue Int, vol.20102, issue.2, pp.174-195, 2018. ,
URL : https://hal.archives-ouvertes.fr/inserm-01653600
Characterization of circulating tumor cells as a reflection of the tumor heterogeneity: myth or reality?, Drug Discov Today, vol.24, issue.3, pp.763-772, 2019. ,
URL : https://hal.archives-ouvertes.fr/inserm-01947472
Tumor-infiltrating macrophages are associated with metastasis suppression in highgrade osteosarcoma: a rationale for treatment with macrophage activating agents, Clin Cancer Res, vol.17, pp.2110-2119, 2011. ,
The concept of immunological surveillance, Prog Exp Tumor Res, vol.13, pp.1-27, 1970. ,
, , 2018.
, Combining PARP inhibition, radiation, and immunotherapy: A possible strategy to improve the treatment of cancer?, Int J Mol Sci, vol.19, issue.12
The neoepitope landscape in pediatric cancers, Genome Med, vol.9, issue.1, p.78, 2017. ,
Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group, Cancer, vol.115, pp.5339-5387, 2009. ,
, , 2015.
, Phase 1 study of intratumoral Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus, in pediatric cancer patients, Mol Ther, vol.23, issue.3, pp.602-608
The genomic landscape of pediatric Ewing sarcoma, Cancer Discov, vol.4, issue.11, pp.1326-1341, 2014. ,
Antitumor activity associated with prolonged persistence of adoptively transferred NY-ESO-1 c259 T cells in synovial sarcoma, Cancer Discov, vol.8, issue.8, pp.944-957, 2018. ,
Oncogenic functions of the cancer-testis antigen SSX on the proliferation, survival, and signaling pathways of cancer cells, PLoS One, vol.9, issue.4, p.95136, 2014. ,
, , 2018.
, Myelolytic treatments enhance oncolytic herpes virotherapy in models of Ewing sarcoma by modulating the immune microenvironment, Mol Ther Oncolytics, vol.11, pp.62-74
Genetically modified T-cell therapy for the treatment of osteosarcoma: an update, J Clin Cell Immunol, vol.7, issue.2, 2016. ,
B7-H4 expression is associated with tumor progression and prognosis in patients with osteosarcoma, Biomed Res Int, p.156432, 2015. ,
Anti-PD-1 therapy redirects macrophages from an M2 to an M1 phenotype inducing regression of OS lung metastases, Cancer Med, vol.7, issue.6, pp.2654-2664, 2018. ,
Dysregulation of macrophage polarization is associated with the metastatic process in osteosarcoma, Oncotarget, vol.7, issue.48, pp.78343-78354, 2016. ,
URL : https://hal.archives-ouvertes.fr/inserm-01466103
The three Es of cancer immunoediting, Annu Rev Immunol, vol.22, pp.329-60, 2004. ,
The role of osteoclasts and tumourassociated macrophages in osteosarcoma metastasis, Biochim Biophys Acta, vol.1826, issue.2, pp.434-476, 2012. ,
Effectiveness evaluation of dendritic cell immunotherapy for osteosarcoma on survival rate and in vitro immune response, Genet Mol Res, vol.14, issue.4, pp.11763-70, 2015. ,
, , 2017.
, Memory T cells expressing an NKG2D-CAR efficiently target osteosarcoma cells, Clin Cancer Res, vol.23, pp.5824-5835
Activated and expanded natural killer cells target osteosarcoma tumor initiating cells in an NKG2D-NKG2DL dependent manner, Cancer Lett, vol.368, issue.1, pp.54-63, 2015. ,
Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on short-term incubation with zoledronic acid, Blood, vol.110, issue.3, pp.921-927, 2007. ,
?? T Cells: Unexpected Regulators of Cancer Development and Progression, Trends Cancer, vol.3, issue.8, pp.561-570, 2017. ,
, , 2008.
, Membrane-associated phospholipase A1 beta (LIPI) Is an Ewing tumour-associated cancer/testis antigen, Pediatr Blood Cancer, vol.51, issue.2, pp.228-234
IL-34 induces the differentiation of human monocytes into immunosuppressive macrophages. antagonistic effects of GM-CSF and IFN?, PLoS One, vol.8, issue.2, p.56045, 2013. ,
,
, CD8 + /FOXP3 + ratio in osteosarcoma microenvironment separates survivors from nonsurvivors: a multicentre validated retrospective study. Oncoimmunology 4; e990800
Oncolytic adenoviruses as a therapeutic approach for osteosarcoma: A new hope, J Bone Oncol, vol.9, pp.41-47, 2016. ,
, , 2010.
, Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells, Cancer Res, vol.70, issue.6, pp.2235-2279
Role of macrophage targeting in the antitumor activity of trabectedin, Cancer Cell, vol.23, issue.2, pp.249-62, 2013. ,
Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group, Lancet Oncol, vol.19, issue.10, pp.30438-30446, 2018. ,
Inhibition of IL-18-mediated myeloid derived suppressor cell accumulation enhances anti-PD1 efficacy against osteosarcoma cancer, J Bone Oncol, vol.9, pp.59-64, 2017. ,
Aerosol interleukin-2 induces natural killer cell proliferation in the lung and combination therapy improves the survival of mice with osteosarcoma lung metastasis, Pediatr Blood Cancer, vol.61, issue.8, pp.1362-1370, 2014. ,
CD163(+) M2-type tumor-associated macrophage support the suppression of tumor-infiltrating T cells in osteosarcoma, Int Immunopharmacol, vol.34, pp.101-106, 2016. ,
Combination therapy with L-arginine and ?-PD-L1 antibody boosts immune response against osteosarcoma in immunocompetent mice, Cancer Biol Ther, vol.18, issue.2, pp.94-100, 2017. ,
In vitro generation of cytotoxic T lymphocyte response using dendritic cell immunotherapy in osteosarcoma, Oncol Lett, vol.12, issue.2, pp.1101-1106, 2016. ,
Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma, Sci Rep, vol.6, p.30093, 2016. ,
Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype, Mod Pathol, vol.29, issue.9, pp.1028-1065, 2016. ,
A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma, Cancer Immunol Immunother, vol.64, issue.10, pp.1251-60, 2015. ,
Cancer-testis antigens MAGEA proteins are incorporated into extracellular vesicles released by cells, Oncotarget, vol.10, issue.38, pp.3694-3708, 2019. ,
, , 2012.
, NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: significance for NY-ESO-1-based targeted therapy and differential diagnosis, Mod Pathol, vol.25, issue.6, pp.854-858
Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study, Eur J Cancer, vol.119, pp.151-157, 2019. ,
In vitro generation of anti-osteosarcoma cytotoxic activity using dendritic cells loaded with heat shock protein 70-peptide complexes, Fetal Pediatr Pathol. 1-12, 2019. ,
Sensitization of human osteosarcoma cells to Vg9d2 T cell mediated cytotoxicity by zoledronate, J Orthop Res, vol.30, issue.5, pp.824-854, 2012. ,
, , 2002.
, Cancer/testis antigen CSAGE is concurrently expressed with MAGE in chondrosarcoma, Gene, vol.285, issue.1-2, pp.269-78
Function of CSF1 and IL34 in Macrophage Homeostasis, Inflammation, and Cancer, 2019. ,
, , vol.10, 2019.
, , 1987.
, Neuroectoderm-associated antigens on Ewing's sarcoma cell lines, Cancer Res, vol.47, issue.1, pp.183-187
Trastuzumab enhanced the cytotoxicity of V?9V?2 T cells against zoledronate-sensitized osteosarcoma cells, Int Immunopharmacol, vol.28, issue.1, pp.160-167, 2015. ,
Unscrambling the genomic chaos of osteosarcoma reveals extensive transcript fusion, recurrent rearrangements and frequent novel TP53 aberrations, Oncotarget, vol.7, issue.5, pp.5273-88, 2016. ,
, , 2019.
, Preclinical evaluation of bispecific adaptor molecule controlled folate receptor CAR-T cell therapy with special focus on pediatric malignancies. Front Oncol, vol.9, p.151
Combination immunotherapy with ?-CTLA-4 and ?-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma, J Immunother Cancer, vol.3, p.21, 2015. ,
, , 2018.
, Immunohistochemical analysis and prognostic significance of PD-L1, PD-1, and CD8+ tumor-infiltrating lymphocytes in Ewing's sarcoma family of tumors (ESFT), Virchows Arch, vol.472, issue.5, pp.815-824
Immune function and diversity of osteoclasts in normal and pathological conditions. Front Immunol, vol.10, p.1408, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02402778
Pannexin-1-mediated intracellular delivery of muramyl dipeptide induces caspase-1 activation via cryopyrin/NLRP3 independently of Nod2, J Immunol, vol.180, issue.6, pp.4050-4057, 2008. ,
Assessment of programmed deathligand 1 expression and tumor-associated immune cells in pediatric cancer tissues, Cancer, vol.123, issue.19, pp.3807-3815, 2017. ,
,
, CAR T cells targeting B7-H3, a pan cancer antigen, demonstrate potent preclincial activity against pediatric solid tumors and brain tumors, Clin Cancer Res, vol.25, issue.8, pp.2560-2574
The oncolytic adenovirus ?24-RGD in combination with cisplatin exerts a potent antiosteosarcoma activity, J Bone Miner Res, vol.29, issue.10, pp.2287-2296, 2014. ,
Profiling targetable immune checkoints in osteosarcoma, Oncoimmunology, vol.7, issue.12, p.1475873, 2018. ,
Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group, J Clin Oncol, vol.26, pp.633-638, 2008. ,
Phase 1/2 study of immunotherapy with dendritic cells pulsed with autologous tumor lysate in patients with refractory bone and soft tissue sarcoma, Cancer, vol.123, issue.9, pp.1576-1584, 2017. ,
Current and emerging targets in immunotherapy for osteosarcoma, J Oncol, p.7035045, 2019. ,
Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases, Expert Rev Anticancer Ther, vol.8, pp.151-159, 2008. ,
Osteosarcoma : current status of immunotherapy and future trends, Oncol Rep, vol.15, issue.3, pp.693-700, 2006. ,
URL : https://hal.archives-ouvertes.fr/inserm-00667509
Positively selected enhancer elements endow osteosarcoma cells with metastatic competence, Nat Med, vol.24, issue.2, pp.176-185, 2018. ,
Osteosarcoma cell line growth inhibition by zoledronate-stimulated effector cells, Cell Immunol, vol.249, issue.2, pp.63-72, 2007. ,
,
, Macrophage delivery of an oncolytic virus abolishes tumor regrowth and metastasis after chemotherapy or irradiation, Cancer Res, vol.73, issue.2, pp.490-495
Liposomal muramyl tripeptide phosphatidylethanolamine: Targeting and activating macrophages for adjuvant treatment of osteosarcoma, Curr Cancer Drug Targets, vol.6, issue.2, pp.123-156, 2006. ,
Tumor-associated macrophages: from mechanisms to therapy, Immunity, vol.41, pp.49-61, 2014. ,
Macrophages inhibit human osteosarcoma cell growth after activation with the bacterial cell wall derivative liposomal muramyl tripeptide in combination with interferon, J Exp Clin Cancer Res, vol.33, p.27, 2014. ,
, , 2017.
, PD-L1 expression and role of CD8/TIA-1 lymphocytes in localized osteosarcoma patients treated within protocol ISG-OS1, Tumoral immune-infiltrate (IF), vol.8, pp.111836-111846
PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models, Mol Cancer, vol.16, issue.1, p.86, 2017. ,
, , 2012.
, NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine, PLoS One, vol.7, issue.2, p.32165
Novel therapeutic approaches in chondrosarcoma, Future Oncol, vol.13, issue.7, pp.637-648, 2017. ,
Trabectedin overrides osteosarcoma differentiative block and reprograms the tumor immune environment enabling effective combination with immune checkpoint inhibitors, Clin Cancer Res, vol.23, issue.17, pp.5149-5161, 2017. ,
, , 2018.
, Comparative transcriptome analysis quantifies immune cell transcript levels, metastatic progression, and survival in osteosarcoma, Cancer Res, vol.78, issue.2, pp.326-337
Coinhibitory pathways in the B7-CD28 ligand-receptor family, Immunity, vol.44, issue.5, pp.955-72, 2016. ,
Interleukin-34 promotes tumor progression and metastatic process in osteosarcoma trhough induction of angiogenesis and macrophage recruitment, Int J Cancer, vol.137, pp.73-85 ,
A curative treatment strategy using tumor debulking surgery combined with immune checkpoint inhibitors for advanced pediatric solid tumors: An in vivo study using a murine model of osteosarcoma, J Pediatr Surg, vol.53, issue.12, pp.2460-2464, 2018. ,
?? T cells in cancer, Nat Rev Immunol, vol.15, issue.11, pp.683-91, 2015. ,
Description of the immune microenvironment of chondrosarcoma and contribution to progression, Oncoimmunology, vol.6, issue.2, p.1265716, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01795707
Programmed cell death ligand 1 (PD-L1) expression is not a predominant feature in Ewing sarcomas, Pediatr Blood Cancer, vol.65, issue.1, 2018. ,
Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy, Cancer Immunol Immunother, vol.66, issue.1, pp.119-128, 2017. ,
Expression and prognostic relevance of PRAME in primary osteosarcoma, Biochem Biophys Res Commun, vol.419, issue.4, pp.801-808, 2012. ,
Circulating tumor cells as a tool for assessing tumor heterogeneity, Theranostics, vol.9, issue.16, pp.4580-4594, 2019. ,
URL : https://hal.archives-ouvertes.fr/inserm-02110266
Advances in immune checkpoint inhibitors for bone sarcoma therapy, J Bone Oncol, vol.15, p.100221, 2019. ,
, , 2005.
, Phenotypic and functional analysis of lymphocytes infiltrating osteolytic tumors: use as a possible therapeutic approach of osteosarcoma, BMC Cancer, vol.5, p.123
Expression of a newly defined tumor-rejection antigen SART3 in musculoskeletal tumors and induction of HLA class I-restricted cytotoxic T lymphocytes by SART3-derived peptides, J Orthop Res, vol.19, issue.3, pp.346-351, 2001. ,
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial, Lancet Oncol, vol.18, issue.11, pp.30624-30625, 2017. ,
Expression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8 + lymphocytes in primary sarcomas is subtype dependent, Oncotarget, vol.8, issue.41, pp.71371-71384, 2017. ,
Valproic acid combined with zoledronate enhance ?? T cell-mediated cytotoxicity against osteosarcoma cells via the accumulation of mevalonate pathway intermediates, p.377, 2018. ,
B7-H3 is overexpressed in patients suffering osteosarcoma and associated with tumor aggressiveness and metastasis, PLoS One, vol.8, issue.8, p.70689, 2013. ,
Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma, J Exp Clin Cancer Res, vol.38, issue.1, p.168, 2019. ,
, Decitabine Enhances V?9V?2 T Cell-Mediated Cytotoxic Effects on Osteosarcoma Cells via the NKG2DL-NKG2D Axis. Front Immunol, vol.9, p.1239, 2018.
, J Clin Oncol, vol.10, issue.2, pp.188-193, 2018.
Metastatic immune infiltrates correlate with those of the primary tumor in canine osteosarcoma, Vet Comp Oncol, vol.17, issue.3, pp.242-252, 2019. ,
Irradiation enhanced the effects of PD-1 blockade in brain metastatic osteosarcoma, J Bone Oncol, vol.12, pp.61-64, 2018. ,
Expression of PD-L1/PD-L2 is associated with high proliferation index of Ki-67 but not with TP53 overexpression in chondrosarcoma, Int J Biol Markers, vol.1724600818774464, 2018. ,
Expression of B7-H3 in cancer tissue during osteosarcoma progression in nude mice, Genet Mol Res, vol.14, issue.4, pp.14253-61, 2015. ,
The XAGE family of cancer/testis-associated genes: alignment and expression profile in normal tissues, melanoma lesions and Ewing's sarcoma, Int J Cancer, vol.99, issue.3, pp.361-369, 2002. ,
PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse, Hematol Oncol, vol.11, issue.1, p.16, 2018. ,
PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse, J Hematol Oncol, vol.11, issue.1, p.16, 2018. ,
All-trans retinoic acid prevents osteosarcoma metastasis by inhibiting M2 polarization of tumor-associated macrophages, Cancer Immunol Res, vol.5, pp.547-559, 2017. ,
Cancer-testis antigens expressed in osteosarcoma identified by gene microarray correlate with a poor patient prognosis, Cancer, vol.118, issue.7, pp.1845-1855, 2012. ,